KRAS and colorectal cancer: In wild-type Kirsten Ras (KRAS) colorectal cancer patients treated with cetuximab, the median progression-free survival and OS were 6.3 and 13.6 months in the HER3− group, 2.8 and 10.5 months in the HER3+ group, HER3+ seemed to be a negative prognostic factor in wild-type KRAS colorectal cancer patients, the combined analysis of HER3 and KRAS might be an effective strategy for better selection of responding colorectal cancer patients [23].